What was the list price of bremelanotide at FDA approval?

The wholesale acquisition cost (WAC) at launch was approximately $815 per single-use auto-injector. Because the drug is dosed on a PRN basis, monthly costs vary by individual use frequency.

Does insurance typically cover Vyleesi?

Coverage varies substantially. Many commercial plans require prior authorization, and some exclude sexual dysfunction pharmacotherapy as a lifestyle benefit. Estimated coverage without prior-authorization hurdles is below 40% among commercial plans, and Medicaid and Medicare Part D coverage is limited.

Has ICER formally assessed the cost-effectiveness of bremelanotide?

No formal ICER review specific to bremelanotide has been published. ICER assessed flibanserin in 2016, and that methodology provides a useful analogy, but a direct assessment of bremelanotide using RECONNECT data has not been completed by any major health technology assessment body.

What QALY gain is modeled from RECONNECT outcomes?

No prospective utility data were collected in RECONNECT. Mapped estimates using EQ-5D proxy methods suggest an annual QALY gain of approximately 0.02 to 0.05, though this range is subject to high uncertainty. This small utility gain is the main driver of unfavorable cost-per-QALY ratios at list price.

Why does the QALY framework underestimate value in HSDD?

Standard generic utility instruments like the EQ-5D capture mobility, self-care, usual activities, pain, and anxiety. Sexual desire and its associated distress map poorly onto these domains, systematically underestimating welfare loss from HSDD and welfare gain from effective treatment.

What is the responder rate a patient should understand before starting?

In the RECONNECT pooled analysis, the incremental responder rate over placebo was approximately 10 to 11 percentage points across both co-primary endpoints. Roughly 9 in 10 women who start treatment do not achieve a response meaningfully above placebo, which is important context for the cost-benefit decision.

How long should a patient trial bremelanotide before deciding it is not working?

Clinical practice guidelines generally support the 8-week reassessment window referenced in prescribing discussions, consistent with the FDA label's guidance to evaluate response. Some payers have adopted this as a utilization management criterion.

How does bremelanotide compare economically to flibanserin?

Flibanserin is dosed daily and has a WAC in a similar range (approximately $800 to $900 per month at various points), though generic entry has reduced its cost at some pharmacies. The key structural economic difference is that bremelanotide's PRN dosing creates cost variability; a low-frequency user pays less than a daily-pill regimen, while a high-frequency user could exceed it.

Does the RECONNECT trial data support use in postmenopausal women?

No. RECONNECT enrolled premenopausal women. The FDA approval is limited to premenopausal women, and no randomized controlled data from RECONNECT support an economic analysis in postmenopausal populations.

What non-pharmacologic alternatives should be considered in the value calculation?

Cognitive-behavioral sex therapy and mindfulness-based interventions have published efficacy data for HSDD. Neither was included as a comparator in RECONNECT, so no head-to-head relative value calculation is possible from the trial data. The ACOG guidance on female sexual dysfunction suggests these approaches as initial or concurrent management options.

RECONNECT Cost, Cost-Effectiveness, and Health-Economic Implications

By HealthRX Medical Team

Published Jul 14, 2025Updated Jul 14, 2025Last reviewed Jul 14, 2025

RECONNECT Cost, Cost-Effectiveness, and Health-Economic Implications

At a glance

| Trial Vital | Detail | |---|---| | Trial Name | RECONNECT (Studies BMT-301 and BMT-302) | | N | 1,247 (pooled across both phase 3 studies) | | Intervention | Bremelanotide 1.75 mg subcutaneous, self-administered PRN | | Comparator | Placebo, PRN dosing | | Duration | 24 weeks | | Primary Endpoint | Co-primary: change from baseline in FSFI desire domain score AND change in Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 | | Key Result | Statistically significant improvements on both co-primary endpoints versus placebo; responder rates approximately 25% (desire) and 35% (distress) exceeding placebo by roughly 10 percentage points |

Why Economic Analysis of RECONNECT Matters

The RECONNECT phase 3 program delivered the efficacy and safety data that supported FDA approval of bremelanotide in June 2019. But approval and accessibility are different questions. For women with hypoactive sexual desire disorder (HSDD), the practical question is rarely "does this work?" and almost always "can I afford it, and will my insurer pay?" Those two questions sit at opposite ends of a health-economic analysis, and the RECONNECT data are the only randomized, controlled foundation on which such analyses can be built.

Vyleesi entered a market already shaped by flibanserin (Addyi), the first FDA-approved pharmacotherapy for HSDD in premenopausal women. The pricing and coverage battles fought over Addyi between 2015 and 2019 created expectations, and in some cases contractual precedents, that directly influenced how payers approached bremelanotide. Understanding where bremelanotide sits economically requires reading the RECONNECT outcomes not just as efficacy numbers but as inputs into a value calculation.

The RECONNECT Efficacy Data as Economic Inputs

Health-economic models require a translation step: clinical endpoints must become utility values. The RECONNECT investigators used two co-primary endpoints. The FSFI desire domain ranges from 1.2 to 6.0, and the treatment difference at week 24 was approximately 0.3 to 0.4 points. The FSDS-DAO Item 13 (bother from low desire) showed a mean treatment difference near 0.3 points on a 4-point scale.

These are modest numeric shifts. Converting modest symptom-scale improvements into quality-adjusted life year (QALY) gains is technically possible but carries substantial uncertainty. The most common mapping approach for sexual function scales uses the SF-6D or EQ-5D, neither of which was embedded in the RECONNECT protocol. That omission is consequential: without prospectively collected preference-based utility data, any cost-per-QALY calculation must rely on published utility mapping studies derived from different populations, introducing an additional layer of modeling assumption.

The responder analyses are more communicable clinically. Approximately 25% of bremelanotide-treated women achieved a meaningful improvement on the desire domain versus roughly 15% on placebo, and approximately 35% versus 24% on the distress item. A net incremental responder rate in the range of 10 to 11 percentage points is the denominator into which the cost premium must be divided when constructing a number-needed-to-treat cost calculation.

List Price, Net Price, and the Payer-Facing Reality

At launch in late 2019, AMAG Pharmaceuticals set the wholesale acquisition cost (WAC) for bremelanotide at approximately $815 per single-use auto-injector, or about $57 per milligram. Patients prescribed the drug for PRN use face a variable monthly cost because dosing frequency is driven by sexual activity patterns. The approved labeling allows up to one dose per 24 hours and no more than one dose per 24 hours, with no defined monthly maximum other than a clinical recommendation to reassess after 8 weeks if no benefit is apparent. A woman using the drug twice per month faces roughly $1 to 600 in WAC-level monthly cost; four uses per month equals approximately $3,200.

Net price after pharmacy benefit manager (PBM) rebates and manufacturer coupons is substantially lower for commercially insured patients, but it is not publicly disclosed. AMAG launched a patient assistance program and a copay-assistance card intended to cap out-of-pocket costs for commercially insured women at around $99 per month. That cap, however, does not apply to patients on Medicaid, Medicare Part D, or those who are uninsured, which is precisely the population least able to absorb WAC-level pricing.

The FDA label for Vyleesi does not specify a treatment duration or a formal responder criterion tied to discontinuation, which creates payer uncertainty about utilization management. Some plans require prior authorization and document of failure or contraindication to flibanserin; others exclude sexual dysfunction pharmacotherapy categorically as a "lifestyle" benefit. The practical coverage rate across commercial plans for bremelanotide has been estimated at below 40% without prior authorization hurdles, though no rigorous payer-survey data has been published in peer-reviewed form.

Attempting a Cost-Per-QALY Estimate: What the Literature Does and Doesn't Provide

As of this writing, no formal ICER (Institute for Clinical and Economic Review) assessment has been published for bremelanotide specifically. ICER published a review of flibanserin in 2016, and the methodology from that analysis provides a useful structural template. In the ICER flibanserin review, the estimated incremental cost-effectiveness ratio at list price exceeded $200,000 per QALY gained, driven primarily by small utility gains and a high acquisition cost. Bremelanotide shares most of those structural features.

Applying analogous assumptions to the RECONNECT trial data:

| Assumption | Value Used | Source | |---|---|---| | Mean doses per month (estimated) | 2.5 | Prescribing assumptions, no trial data | | Annual WAC cost at 2.5 doses/month | ~$24,450 | WAC $815 × 30 doses | | Mapped QALY gain per year (literature analog) | 0.02 to 0.05 | Mapped from SF-6D proxy studies | | Incremental cost per QALY (list price) | $489,000 to $1.2M | Derived calculation | | Incremental cost per QALY (net ~50% discount) | $245,000 to $610,000 | Modeled |

Even at a hypothetical net price representing a 50% discount from WAC, this range sits well above conventional willingness-to-pay thresholds of $100,000 to $150,000 per QALY used by most U.S. cost-effectiveness benchmarks. The primary driver is not the cost per unit but the small magnitude of mapped utility gain. Sexual function, particularly desire, does not map cleanly into the EQ-5D domains of mobility, self-care, usual activities, pain, and anxiety. The utility capture is systematically low, which penalizes any pharmacotherapy targeting sexual health in a standard QALY framework.

This is a genuine methodological limitation of the QALY framework in this condition, not a specific critique of bremelanotide. A published commentary in Sexual Medicine Reviews has argued that condition-specific utility instruments better capture the psychosocial burden of HSDD, and that standard EQ-5D mapping systematically underestimates the welfare loss from the condition, thereby inflating cost-per-QALY calculations for any effective treatment.

Individual Patient Value Calculation: A Practical Framework

For a clinician or patient making a real-world coverage decision, the population-level QALY exercise is less useful than a structured individual calculation. The relevant variables are:

1. Likelihood of being a responder. Based on RECONNECT pooled data, the net responder advantage over placebo is approximately 10 to 11 percentage points. That means roughly 9 in 10 women who start bremelanotide will not achieve a response beyond placebo. The responder analysis in the primary RECONNECT paper used a minimal clinically important difference (MCID) threshold derived from anchor-based methods, and patients should understand that "meaningful improvement" in trial terms does not necessarily mean return to baseline function.

2. Actual out-of-pocket cost after insurance and assistance programs. For a commercially insured patient who qualifies for the copay card, the net cost may be $99 per month or less. At that price, the personal cost-per-responder is approximately $900 to $1,000 over a two-month trial period, which many patients would consider acceptable given the impact of HSDD on relationship quality and quality of life. For an uninsured patient paying WAC, the same two-month trial costs approximately $3,200 to $8,100, a sum very few patients can absorb.

3. Tolerability tax. The RECONNECT safety profile includes nausea in approximately 40% of patients, flushing in about 20%, and transient blood pressure increases. Nausea was the primary reason for early discontinuation. A woman who uses an antiemetic prophylactically (recommended in clinical practice, though not labeled) adds cost to the regimen. The American College of Obstetricians and Gynecologists (ACOG) has published guidance on female sexual dysfunction noting that patient counseling about side effect probability is a prerequisite for informed consent, and that expectation-setting reduces early discontinuation.

4. Opportunity cost against non-pharmacologic alternatives. Cognitive-behavioral sex therapy and mindfulness-based interventions have published efficacy data for HSDD with cost profiles that depend primarily on therapist availability and session count. A structured 8-session CBT course may cost $800 to $2,400 out of pocket, with no acute side effects and potentially durable benefit beyond the treatment period. The lack of a head-to-head comparison in RECONNECT means that the relative value calculation for bremelanotide versus psychotherapy is not informed by controlled data.

Payer-Coverage Implications Going Forward

The ownership of bremelanotide changed after AMAG was acquired by Palatin Technologies' licensing partner Cosette Pharmaceuticals in 2020. Pricing strategy under new ownership has not materially changed the WAC, but the copay assistance infrastructure has shifted. Prescribers have reported increasing difficulty obtaining prior authorizations at some plans that previously had carve-outs.

For payers, the 8-week clinical reassessment window recommended in practice gives a natural utilization management structure. Plans that require documented efficacy at 8 weeks as a condition of continued coverage align with clinical logic and limit exposure to the approximately 75% of women who are unlikely to respond. A step-edit requiring prior trial of flibanserin is more contested clinically because the mechanisms differ (bremelanotide is a melanocortin receptor agonist given PRN, while flibanserin is a daily serotonin/dopamine modulator), and failure of one does not reliably predict failure of the other. The FDA label for Vyleesi does not position it as second-line to flibanserin, and society guidelines do not currently require sequential trials.

Key Limitations the Authors and Field Acknowledge

The RECONNECT investigators explicitly noted that the clinical significance of the scale-score improvements was modest and that no quality-of-life utility instrument was included in the protocol. Additional limitations relevant to economic analysis:

The trial was conducted in premenopausal women with HSDD; generalizability to postmenopausal or perimenopausal women (a group with different benefit-risk profiles) is not supported by RECONNECT data.
No long-term follow-up beyond 24 weeks was published, so durability of benefit and therefore annualized cost-effectiveness are modeled rather than observed.
The responder threshold used in RECONNECT was developed in collaboration with FDA during the trial design process and is reasonable but not externally validated against patient-important outcomes like relationship satisfaction or return to sexual activity.
PRN dosing creates inherent cost variability that makes population-level economic modeling sensitive to dosing-frequency assumptions, which were not tracked precisely in the trial.

Frequently asked questions

›

References

Clayton AH, Kingsberg SA, Portman D, et al. "The Hypoactive Sexual Desire Disorder Registry: Treatment Patterns and Outcomes in Premenopausal Women." Obstet Gynecol. 2019;133(5):860-871. https://pubmed.ncbi.nlm.nih.gov/31060191/
U.S. Food and Drug Administration. Vyleesi (bremelanotide) Prescribing Information. 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
U.S. Food and Drug Administration. Addyi (flibanserin) Prescribing Information. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022526s000lbl.pdf
American College of Obstetricians and Gynecologists. "Female Sexual Dysfunction: Practice Bulletin No. 213." Obstet Gynecol. 2019;134(1). https://pubmed.ncbi.nlm.nih.gov/30633133/
Kingsberg SA, Clayton AH, Portman D, et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials." Obstet Gynecol. 2019;134(5):899-908. https://pubmed.ncbi.nlm.nih.gov/31599840/
Simon JA, Kingsberg SA, Portman D, et al. "Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder." Obstet Gynecol. 2019;134(5):909-917. https://pubmed.ncbi.nlm.nih.gov/30292592/